New platform for controlled and sustained delivery of the EGF receptor tyrosine kinase inhibitor AG1478 using poly(lactic-co-glycolic acid) microspheres

Journal of Microencapsulation

Volumn 27, Issue 3, 2010, Pages 263-271

  Robinson, Rebecca ^a   Bertram, James P ^a   Reiter, Jill L ^b   Lavik, Erin B ^a  

^a Yale University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AG1478; Epidermal growth factor receptor; Microspheres; PLGA; Tyrosine kinase inhibitors

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; MICROSPHERE; POLYGLACTIN;

ANIMAL CELL; ARTICLE; CANCER CELL; CONTROLLED STUDY; EMULSION; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; MICROENCAPSULATION; NONHUMAN; PARTICLE SIZE; RAT; SUSTAINED DRUG RELEASE;

ANIMALS; CARCINOMA; CELL LINE; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; LACTIC ACID; MICROSPHERES; POLYGLYCOLIC ACID; PROTEIN-TYROSINE KINASES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYRPHOSTINS;

EID: 77951494764     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652040903131285     Document Type: Article

References (47)

1. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L. 2001. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11:1911-1914. (Pubitemid 32675316)
2. Busse D, Doughty RS, Ramsey TT, Russell WE, Price JO, Flanagan WM, Shawver LK, Arteaga CL. 2000. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem 275:6987-6995. (Pubitemid 30146243)
3. Ciardiello F, Tortora G. 2008. EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174.
4. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. 2005. FDA drug approval summary: Erlotinib (Tarceva) tablets. Oncologist 10:461-466. (Pubitemid 41266326)
5. Ellis A, Doherty M, Walker F, Weinstock J, Nerrie M, Vitali A, Murphy R, Johns T, Scott A, Levitzki A, McLachlan G, Webster L, Burgess A, Nice E. 2006. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem Pharmacol 71:1422-1434.
6. Ellis A, Nice E, Weinstock J, Levitzki A, Burgess A, Webster L. 2001. Highperformance liquid chromatographic analysis of the tyrphostin AG1478, a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in mouse plasma. J Chromatogr B Biomed Sci Appl 754:193-199. (Pubitemid 32241084)
7. Erschbamer M, Pernold K, Olson L. 2007. Inhibiting epidermal growth factor receptor improves structural, locomotor, sensory, and bladder recovery from experimental spinal cord injury. J Neurosci 27:6428-6435. (Pubitemid 46920375)
8. Fabricant RN, De Larco JE, Todaro GJ. 1977. Nerve growth factor receptors on human melanoma cells in culture. Proc Natl Acad Sci USA 74:565-569. (Pubitemid 8038843)
9. Fawcett J, Asher R. 1999. The glial scar and central nervous system repair. Brain Res Bull 49:377-391. (Pubitemid 29385505)
10. Fu K, Harrell R, Zinski K, Um C, Jaklenec A, Frazier J, Lotan N, Burke P, Klibanov A, Langer R. 2003. A potential approach for decreasing the burst effect of protein from PLGA microspheres. J Pharm Sci 92:1582-1591. (Pubitemid 36929678)
11. Gullick WJ. 1991. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47:87-98.
12. Gupta RK, Chang AC, Griffin P, Rivera R, Guo YY, Siber GR. 1997. Determination of protein loading in biodegradable polymer microspheres containing tetanus toxoid. Vaccine 15:672-678. (Pubitemid 27240483)
13. Han Y, Caday CG, Nanda A, Cavenee WK, Huang HJ. 1996. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res 56:3859-3861. (Pubitemid 26284726)
14. Harari PM. 2004. Epidermal growth factor receptor inhibition strategies in oncology. Endocrine-Related Cancer 11:689-708. (Pubitemid 40065545)
15. Jain R. 2000. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21:2475-2490.
16. Jain R, Shah NH, Malick AW, Rhodes CT. 1998. Controlled drug delivery by biodegradable poly(ester) devices: Different preparative approaches. Drug Dev Ind Pharm 24:703-727.
17. Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, Jungbluth AA, Stockert E, Old LJ, Nice EC, Burgess AW, Scott AM. 2003. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 100:15871-15876.
18. Kari C, Chan TO, Rocha De Quadros M, Rodeck U. 2003. Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage. Cancer Res 63:1-5.
19. Koprivica V, Cho K, Park J, Yiu G, Atwal J, Gore B, Kim J, Lin E, Tessier-Lavigne M, Chen D, He Z. 2005. EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans. Science 310:106-110.
20. Langer R, Folkman J. 1976. Polymers for the sustained release of proteins and other macromolecules. Nature 263:797-800.
21. Levitzki A, Gazit A. 1995. Tyrosine kinase inhibition: An approach to drug development. Science 267:1782-1788.
22. Linggi B, Carpenter G. 2006. ErbB receptors: New insights on mechanisms and biology. Trends Cell Biol 16:649-656.
23. Liu B, Chen H, Johns T, Neufeld A. 2006. Epidermal growth factor receptor activation: An upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury. J Neurosci 26:7532-7540.
24. Liu B, Neufeld A. 2004a. Activation of epidermal growth factor receptor causes astrocytes to form cribriform structures. Glia 46:153-168.
25. Liu B, Neufeld A. 2004b. Activation of epidermal growth factor receptors directs astrocytes to organize in a network surrounding axons in the developing rat optic nerve. Dev Biol 273:297-307.
26. Liu B, Neufeld AH. 2007. Activation of epidermal growth factor receptors in astrocytes: From development to neural injury. J Neurosci Res 85:3523-3529.
27. Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK, Huang HJ. 2001. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95:472-479.
28. Neufeld AH, Liu B. 2003. Glaucomatous optic neuropathy: When glia misbehave. Neuroscientist Rev J Bringing Neurobiol Neurol Psychiatry 9:485-495.
29. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. 1993. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with -lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Contr Rel 25:89-98.
30. Partik G, Hochegger K, Schörkhuber M, Marian B. 1999. Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro. J Cancer Res Clin Oncol 125:379-388.
31. Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG. 2005. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 11:6390-6399.
32. Raymond E, Faivre S, Armand JP. 2000. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60(Suppl 1):15-23; discussion 41-42.
33. Saltzman WM, Fung LK. 1997. Polymeric implants for cancer chemotherapy. Adv Drug Deliv Rev 26:209-230.
34. Segaert S, Van Cutsem E. 2005. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425-1433.
35. Seif R, Cuzin F. 1977. Temperature-sensitive growth regulation in one type of transformed rat cells induced by the tsa mutant of polyoma virus. J Virol 24:721-728.
36. Shive M, Anderson J. 1997. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28:5-24.
37. Silver J, Miller J. 2004. Regeneration beyond the glial scar. Nat Rev Neurosci 5:146-156.
38. Smith G, Strunz C. 2005. Growth factor and cytokine regulation of chondroitin sulfate proteoglycans by astrocytes. Glia 52:209-218.
39. Stern DF, Roberts AB, Roche NS, Sporn MB, Weinberg RA. 1986. Differential responsiveness of myc- and ras-transfected cells to growth factors: Selective stimulation of myc-transfected cells by epidermal growth factor. Mol Cell Biol 6:870-877.
40. Wang H, Katagiri Y, McCann TE, Unsworth E, Goldsmith P, Yu ZX, Tan F, Santiago L, Mills EM, Wang Y, Symes AJ, Geller HM. 2008. Chondroitin-4-sulfation negatively regulates axonal guidance and growth. J Cell Sci 121:3083-3091.
41. Wong RW, Guillaud L. 2004. The role of epidermal growth factor and its receptors in mammalian CNS. Cytokine Growth Factor Rev 15:147-156.
42. Wrann MM, Fox CF. 1979. Identification of epidermal growth factor receptors in a hyperproducing human epidermoid carcinoma cell line. J Biol Chem 254:8083-8086.
43. Yamaguchi K, Anderson JM. 1993. In vivo biocompatability studies of medisorb(R) 65/35 D,L-lactide glycolide coploymer microspheres. J Contr Rel 24 (1-3):81-93.
44. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137.
45. Yiu G, He Z. 2006. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 7:617-627.
46. Zhu XF, Liu ZC, Xie BF, Li ZM, Feng GK, Yang D, Zeng YX. 2001. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett 169:27-32.
47. Zolnik B, Burgess D. 2007. Effect of acidic pH on PLGA microsphere degradation and release. J Contr Rel Official J Contr Rel Soc 122(3): 338-1334